Exploration of piperidine 3D fragment chemical space: synthesis and 3D shape analysis of fragments derived from 20 regio- and diastereoisomers of methyl substituted pipecolinates-Reference-Cited by-同舟云学术

Exploration of piperidine 3D fragment chemical space: synthesis and 3D shape analysis of fragments derived from 20 regio- and diastereoisomers of methyl substituted pipecolinates

Published:2022 Issue:12 Volume:13 Page:1614-1620
ISSN:2632-8682
Container-title:RSC Medicinal Chemistry
language:en
Short-container-title:RSC Med. Chem.

Author:

Jones S. Paul¹,Firth James D.¹^ORCID,Wheldon Mary C.¹,Atobe Masakazu¹²,Hubbard Roderick E.¹³^ORCID,Blakemore David C.⁴,De Fusco Claudia⁵,Lucas Simon C. C.⁶^ORCID,Roughley Stephen D.³^ORCID,Vidler Lewis R.⁷,Whatton Maria Ann⁸,Woolford Alison J.-A.⁹^ORCID,Wrigley Gail L.¹⁰,O'Brien Peter¹^ORCID

Affiliation:

1. Department of Chemistry, University of York, Heslington, York, YO10 5DD, UK

2. Asahi Kasei Pharma Corporation, 632-1 Mifuku, Izunokuni, Shizuoka 410-2321, Japan

3. Vernalis (R&D) Ltd., Granta Park, Abington, Cambridge, CB21 6GB, UK

4. Medicine Design, Pfizer Inc., 445 Eastern Point Road, Groton, CT 06340, USA

5. Bayer AG, Research and Development, Pharmaceuticals, Synthetic Modalities, 13353, Berlin, Germany

6. Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge, CB4 0WG, UK

7. Amphista Therapeutics, The Cori Building, Granta Park, Great Abington, Cambridge CB21 6GQ, UK

8. Evotec (UK) Ltd, Dorothy Crowfoot Hodgkin Campus, 114 Innovation Drive, Milton Park, Abingdon, Oxon, OX14 4RZ, UK

9. Astex Pharmaceuticals, 436 Cambridge Science Park, Milton Road, Cambridge, CB4 0QA, UK

10. Medicinal Chemistry, Oncology R&D, AstraZeneca, Cambridge, UK

Abstract

The synthesis and 3D shape analysis of fragments derived from 20 regio- and diastereoisomers of methyl substituted pipecolinates is described.

Funder

Royal Society

Biotechnology and Biological Sciences Research Council

Engineering and Physical Sciences Research Council

University of York

Asahi Kasei Pharma Corporation

Publisher

Royal Society of Chemistry (RSC)

Subject

Organic Chemistry,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biochemistry

Link

http://pubs.rsc.org/en/content/articlepdf/2022/MD/D2MD00239F

Reference68 articles.

1. Twenty years on: the impact of fragments on drug discovery

2. Vemurafenib: the first drug approved for BRAF-mutant cancer

3. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

4. Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor

5. A successful collaboration between academia, biotech and pharma led to discovery of erdafitinib, a selective FGFR inhibitor recently approved by the FDA

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Accessing a Medicinal-Chemistry-Relevant Chemical Space with sp2–sp3 Hybrid Heterocyclic Fragments;Synthesis;2024-09-09

2. Ultrasound Assisted and SO4-2/SnO2-Catalyzed One-Pot Multicomponent Reaction for the Synthesis of 1,2,3,4,6-Pentasubstituted Piperidines;INDIAN JOURNAL OF HETEROCYCLIC CHEMISTRY;2024-06

3. A guide to bullvalene stereodynamics;Chemical Science;2024